Arix Bioscience plc

("Arix" or "the Company")

Board update

LONDON, 29 March 2021: The board of Arix, (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, has paused its timetable to appoint James Noble and Axel Wieandt as non-executive directors of the Company.

Whilst the board continues to believe that both appointees are highly qualified with relevant experience and expertise, it believes the appointments should be considered within the scope of the Company's recently announced Strategic Implementation Review, (the "Review") which includes the question of board composition.

[ENDS]

For more information, please contact:

Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com

Montfort Communications
Olly Scott

+44(0)78 1234 5205

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com
 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com